Moderate to severe psoriasis treated with infliximab - 53 patients: Patients profile, efficacy and adverse effects;Psoríase moderada a grave tratada com infliximabe em 53 pacientes: Perfil dos pacientes, eficácia e efeitos adversos

Anais Brasileiros de Dermatologia

Volumn 86, Issue 2, 2011, Pages 257-263

  Duarte, Artur Antonio ^a   Chehin, Flavia Barbour ^a  

^a UNIVERSITY OF SANTO AMARO   (Brazil)

Author keywords

Biological treatment; Immunity; Psoriasis; Therapeutics

Indexed keywords

ANTINUCLEAR ANTIBODY; INFLIXIMAB; LIVER ENZYME;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; BRONCHOPNEUMONIA; CLINICAL ASSESSMENT TOOL; COLD LIMB; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; KIDNEY COLIC; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; NAIL PSORIASIS; PHOTOTHERAPY; PSORIASIS; PSORIASIS AREA SEVERITY INDEX; SIDE EFFECT; SWEATING; TACHYCARDIA; TONSILLITIS; TREATMENT DURATION; URINARY TRACT INFECTION; URTICARIA; WEIGHT GAIN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960187321     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962011000200008     Document Type: Article

References (29)

1. Duarte A.A, Pinto J.M. Artrite Psoriásica e comorbidades. p.31-36. In: Consenso Brasileiro de Psoríase 2009 - Sociedade Brasileira de Dermatologia. Rio de Janeiro: Sociedade Brasileira de Dermatologia, 2009.
2. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-320
3. Elder J.T, Nair R.P, Voorhees J.J. Epidemiology and the genetics of psoriasis. J Invest Dermatol. 1994; 102: 24S-27S.
4. Gottlieb A.B. Psoriasis. Immunopathology and Immunomodulation. Dermatol Clin.2001;19:649-657.
5. Chan C.Y, Browning J.C, Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Dermatol Online J. 2008;15;14-12.
6. Patel R.V, Clark L.N, Lebwohl M, Weinberg J.M. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60:1001-1017.
7. Valdés A Mdel P, Schroeder H.F, Roizen G.V, Honeyman M.J, Sánchez M.L. Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade). Rev Med Chil. 2006;134:326-31.
8. Gottlieb A, Korman N.J, Gordon K.B, Feldman S.R, Lebwohl M, Koo J.Y, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2.psoriatic arthritis:overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-864.
9. Reich K, Nestle F.O, Papp K, Ortonne J.P, Evans R, Guzzo C, et al. Infliximab indution and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374.
10. Kleyn C.E, Griffiths C.E. Infliximab for treatment of psoriasis. Expert Opin Biol Ther. 2006;6:797-805.
11. Ko J.M, Gottlieb A.B, Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100-108.
12. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol. 2009;160:8-15.
13. Doherty S.D, Van Voorhees A, Lebwohl M.G, Korman N.J, Young M.S, Hsu S, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59:209-217.
14. Newell E.L, Jain S, Stephens C, Martland G. Infliximab-induced pityriasis lichenoides chronica in a patient with psoriasis. J Eur Acad Dermatol Venereol. 2009;23:230-231.
15. Benucci M, Nenci G, Cappelletti C, Manfredi M. Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases. Recenti Prog Med. 2008;99:363-366.
16. Chaudhari U, Romano P, Mulcahy L.D, Dooley L.T, Baker D.G, Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-1847.
17. Lecluse L.L, Piskin G, Mekkes J.R, Bos J.D, de Rie M.A. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527-536.
18. Gottlieb A.B, Evans R, Li S, Dooley L.T, Guzzo C.A, Baker D, et al. Infliximabe indition therapy for pacients with severe plaque types psoriasis: a randomized double-blind, placebo-controlled trial. J Am Acad dermatol. 2004;51:534-542.
19. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250-256.
20. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-24.
21. Gottlieb A.B. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49(Suppl 2):S112-S117.
22. Moustou A.E, Matekovits A, Dessinioti C, Antoniou C, Sfikakis P.P, Stratigos A.J. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486-504.
23. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156:329-336.
24. Menter A, Feldman S.R, Weinstein G.D, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous VS. intermitten infliximab maintenance regimens over 1 year in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2007;56-31.e1-e15.
25. Finlay A.Y, Khan G.K. Dermatology life quality index (DLQI)- a simple practical measure for routine clinical use. Clin Exp Dermatol.1994;19:210-216.
26. Martins G.A, Arruda L, Mugnaini A.S.B. Validação de questionários de avaliação da qualidade de vida em pacientes de psoríase. An Bras Dermatol. 2004;79:512-535.
27. Sterry W, Barker J, Boehncke W.H, Bos J.D, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis. Br J Dermatol. 2004;151(Suppl 69):3-17.
28. Cuchacovich R, Espinoza C.G, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol. 2008;14:353-356.
29. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-2673.